Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

NCT03344965 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT03344965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03344965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 1, 2018
Completion date
June 30, 2026
Enrollment
114 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

atm gene mutation, brip1 gene mutation, chek2 gene mutation, invasive breast cancer, metastatic breast cancer, nbn gene mutation, palb2 gene mutation, rad51 gene mutation, somatic mutation breast cancer (brca1), somatic mutation breast cancer (brca2)